Astellas Pharma Inc., a global pharmaceutical company committed to turning innovative science into value for patients, has announced the official inauguration of its newly established Scientific Office in Cairo.
As part of Astellas’ long-term commitment to Egypt, the office in Cairo reiterates the company’s strong belief in deepening its roots within the community. This will enable Astellas to better address unmet medical needs, support the local healthcare infrastructure and accelerate the availability of innovative treatments.
Leon Moore, President of International Markets Commercial, Astellas said: “Building a base in Cairo is a significant milestone for Astellas that will enable us to better serve the needs of patients and the healthcare community. We look forward to working closely with the local authorities and healthcare providers to create sustainable solutions aligned with Egypt’s Vision 2030 and healthcare goals. By enhancing our presence in the country, we are better equipped to ensure the availability of our treatments that bring relief and hope to patients and their families.”
Future products and new indications for medications will be prioritized for launch in the country. This includes select oncology medication targeting disease areas such as Acute Myeloid Leukaemia (AML), Urothelial and Gastric Cancer. In addition to its oncology pipeline the company plans to introduce medication to treat anaemia in patients with chronic kidney disease, as well as technologies in regenerative medicine and gene therapy.
Astellas also plans to scale up local investment through education and training in partnership with key stakeholders, industry partners and healthcare providers. These programs will cover a range of topics from disease awareness to education on medication. This is in line with the government’s goal to enhance the quality of healthcare services in Egypt
